FDA accepts filing of abbreviated new drug application for nalmefene HCI autoinjector for the treatment of known or suspected opioid overdose

The opioid antagonist nalmefene is being developed as an autoinjector for use in community settings by people without medical training in the US. Use of the nalmefene autoinjector would not replace the need for emergency medical care.

Source:

Biospace Inc.